Olokizumab
drugOn this page
Also known as CDP-6038CDP6038
Summary
Olokizumab (CHEMBL1743050) is a phase-3 clinical-stage antibody (ATC L04AC23); indicated across 5 conditions including rheumatoid arthritis and severe acute respiratory syndrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- ATC class: L04AC23
- Indications: 5 conditions
- Clinical trials: 15
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1743050 |
| Name | Olokizumab |
| Type | Antibody |
| Max phase | 3 |
| ATC | L04AC23 |
Also known as: CDP-6038, CDP6038, Olokizumab, OLOKIZUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| rheumatoid arthritis | 3 | MONDO:0008383 | EFO:0000685 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| immune system disorder | 3 | MONDO:0005046 | EFO:0000540 |
| Crohn disease | 2 | MONDO:0005011 | EFO:0000384 |
| osteoarthritis | 1 | MONDO:0005178 | MONDO:0005178 |
Clinical trials
Total trials: 15.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 5 |
| PHASE3 | 3 |
| PHASE1 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02760368 | PHASE3 | COMPLETED | Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease |
| NCT02760433 | PHASE3 | COMPLETED | Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease |
| NCT04380519 | PHASE2/PHASE3 | COMPLETED | Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) |
| NCT04452474 | PHASE2/PHASE3 | WITHDRAWN | Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). |
| NCT05187793 | PHASE3 | UNKNOWN | Study of Efficacy of Different Treatment Regimens of Olokizumab |
| NCT01009242 | PHASE1/PHASE2 | COMPLETED | To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate |
| NCT01242488 | PHASE2 | COMPLETED | Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy |
| NCT01296711 | PHASE2 | TERMINATED | Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056 |
| NCT01463059 | PHASE2 | COMPLETED | Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy |
| NCT01533714 | PHASE2 | TERMINATED | The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis |
| NCT01635621 | PHASE2 | WITHDRAWN | A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn’s Disease |
| NCT01262794 | PHASE1 | COMPLETED | Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects |
| NCT01276119 | PHASE1 | COMPLETED | The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males |
| NCT04246762 | PHASE1 | COMPLETED | Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 |
| NCT05196477 | Not specified | COMPLETED | Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).